Lantheus (NASDAQ:LNTH) Stock Price Breaks Below 50 Day Moving Average – What’s Next?

Lantheus Holdings, Inc. (NASDAQ:LNTH) shares passed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $101.41 and traded as low as $99.69. Lantheus shares last traded at $99.72, with a volume of 938,543 shares.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on LNTH shares. Mizuho lowered their target price on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Wednesday, July 29th. Citizens Jmp restated a “market outperform” rating and issued a $115.00 price target on shares of Lantheus in a research note on Monday, June 29th. William Blair set a $102.50 price objective on Lantheus in a research report on Monday, August 3rd. Weiss Ratings cut Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, September 10th. Finally, CJS Securities downgraded Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $108.11.

Lantheus Price Performance

The firm’s fifty day simple moving average is $101.25 and its 200-day simple moving average is $95.47. The firm has a market capitalization of $6.51 billion, a PE ratio of 24.09 and a beta of -0.03. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The firm had revenue of $388.18 million for the quarter, compared to analysts’ expectations of $363.23 million. During the same quarter in the prior year, the company posted $1.57 earnings per share. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. On average, research analysts forecast that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current fiscal year.

Institutional Trading of Lantheus

A number of institutional investors and hedge funds have recently modified their holdings of LNTH. Jupiter Topco LLC bought a new position in shares of Lantheus during the second quarter valued at $575,628,000. Reinhart Partners LLC. increased its holdings in Lantheus by 2.2% in the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after buying an additional 34,501 shares in the last quarter. Carmignac Gestion lifted its stake in Lantheus by 0.9% during the 2nd quarter. Carmignac Gestion now owns 1,340,100 shares of the medical equipment provider’s stock valued at $148,671,000 after acquiring an additional 12,100 shares during the period. Norges Bank purchased a new stake in shares of Lantheus during the 4th quarter valued at about $76,197,000. Finally, Assenagon Asset Management S.A. boosted its holdings in Lantheus by 440.3% in the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after purchasing an additional 582,661 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic imaging agents and radiopharmaceuticals. Its products are designed to help physicians detect, characterize and monitor disease, with applications in cardiology, oncology and other areas of medicine.

The company’s principal products include DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound images, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and assess prostate cancer.